McGregor CGC, Tandon R, Simmons A. Pathogenesis of fistulating Crohn’s disease: a review. Cell Mol Gastroenterol Hepatol. 2023;15(1):1–11.

Article  PubMed  CAS  Google Scholar 

Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County. Minnesota Gastroenterol. 2002;122(4):875–80.

Article  Google Scholar 

Schwartz D, Tagarro I, Díez M, et al. Prevalence of fistulizing Crohn’s disease in the United States: estimate from a systematic literature review attempt and population-based database analysis. Inflamm Bowel Dis. 2019;25(11):1773–9.

Article  PubMed  PubMed Central  Google Scholar 

Gecse K, Khanna R, Stoker J, et al. Fistulizing Crohn’s disease: diagnosis and management. United European Gastroenterol J. 2013;1(3):206–13.

Article  PubMed  PubMed Central  Google Scholar 

Dunleavy KA, Pardi DS. Biologics: how far can they go in Crohn’s disease? Gastroenterol Rep (Oxf). 2022;10:goac049.

Article  PubMed  PubMed Central  Google Scholar 

Wetwittayakhlang P, Al Khoury A, Hahn GD, et al. The optimal management of Fistulizing Crohn’s disease: evidence beyond randomized clinical trials. J Clin Med. 2022;11(11):3045.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Menditto E, Cahir C, Malo S, et al. Persistence as a robust indicator of medication adherence-related quality and performance. Int J Environ Res Public Health. 2021;18(9):4872.

Article  PubMed  PubMed Central  Google Scholar 

Mahlich J, May M, Feig C, et al. Persistence with biologic therapy and associated costs of patients with inflammatory bowel disease: a German retrospective claims data analysis. Crohns Colitis 360. 2021;3(2):otab011.

Article  PubMed  PubMed Central  Google Scholar 

Jalah R, Rosati M, Ganneru B, et al. The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem. 2013;288(9):6763–76.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Janssen Pharmaceutical Companies. STELARA (Ustekinumab) [package insert]. U.S. Food and Drug Administration. 2016 [cited 2021 7 July]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf

D’Amico F, Peyrin-Biroulet L, Danese S. Ustekinumab in Crohn’s disease: new data for positioning in treatment algorithm. J Crohns Colitis. 2022;16(Supplement_2):ii30–41.

Article  PubMed  PubMed Central  Google Scholar 

Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal Fistulizing Crohn’s disease. Gastroenterology. 2021;160(7):2496–508.

Article  PubMed  Google Scholar 

Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–28.

Article  PubMed  CAS  Google Scholar 

Teresa VD, Raul OM, Marisa I, et al. Effectiveness and safety of ustekinumab in bio-naive Crohn’s disease patients: a multicentre observational retrospective study. Therap Adv Gastroenterol. 2023;16:17562848231153560.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lorenzo Gonzalez L, Valdes Delgado T, Vazquez Moron JM, et al. Ustekinumab in Crohn’s disease: real-world outcomes and predictors of response. Rev Esp Enferm Dig. 2022;114(5):272–9.

PubMed  Google Scholar 

Yao J, Zhang H, Su T, et al. Ustekinumab promotes radiological fistula healing in perianal fistulizing Crohn’s disease: a retrospective real-world analysis. J Clin Med. 2023;12(3):939.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bacsur P, Matuz M, Resal T, et al. Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study. Therap Adv Gastroenterol. 2022;15:17562848221144348.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhdanava M, Ding Z, Manceur AM, et al. Treatment persistence among bio-naive patients with Crohn’s disease initiated on ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(4):533–43.

Article  PubMed  CAS  Google Scholar 

Zhdanava M, Zhao R, Manceur AM, et al. Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab. J Manag Care Spec Pharm. 2023;29(8):907–16.

PubMed  PubMed Central  Google Scholar 

Ko Y, Paramsothy S, Yau Y, et al. Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Aliment Pharmacol Ther. 2021;54(3):292–301.

Article  PubMed  CAS  Google Scholar 

Bressler B, Jones J, In TSH, et al. Real-world persistence of Ustekinumab in the treatment of inflammatory bowel disease. Adv Ther. 2023;40(10):4421–39.

Article  PubMed  CAS  Google Scholar 

Xu C, Ferrante SA, Fitzgerald T, et al. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29(1):90–100.

PubMed  Google Scholar 

Zhdanava M, Ding Z, Manceur AM, et al. Long-term persistence and other treatment patterns among bio-naive patients with Crohn’s disease treated with ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(9):1215–25.

Article  PubMed  CAS  Google Scholar 

Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507.

PubMed  Google Scholar 

Zhou Z, Ouboter LF, Peeters K, et al. Crohn’s Disease-Associated and Cryptoglandular Fistulas: Differences and Similarities. J Clin Med. 2023;12(2):466.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Godoy Brewer GM, Salem G, Afzal MA, et al. Ustekinumab is effective for perianal fistulising Crohn’s disease: a real-world experience and systematic review with meta-analysis. BMJ Open Gastroenterol. 2021;8(1):e000702.

Article  PubMed  PubMed Central  Google Scholar 

Vasudevan A, Bruining DH, Loftus EV Jr, et al. Approach to medical therapy in perianal Crohn’s disease. World J Gastroenterol. 2021;27(25):3693–704.

Article  PubMed  PubMed Central  Google Scholar 

Barreiro-de Acosta M, Fernandez-Clotet A, Mesonero F, et al. Long-term outcomes of biological therapy in crohn’s disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU. Am J Gastroenterol. 2023;118(6):1036–46.

Article  PubMed  CAS  Google Scholar 

Lee JL, Yoon YS, Yu CS. Treatment strategy for perianal fistulas in crohn disease patients: the surgeon’s point of view. Ann Coloproctol. 2021;37(1):5–15.

Article  PubMed  PubMed Central  Google Scholar